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Colonization of the fetal and infant gut microbiome
results in dynamic changes in diversity, which can
impact disease susceptibility. To examine the rela-
tionship between human gut microbiome dynamics
throughout infancy and type 1 diabetes (T1D), we
examined a cohort of 33 infants genetically predis-
posed to T1D. Modeling trajectories of microbial
abundances through infancy revealed a subset of mi-
crobial relationships shared across most subjects.
Although strain composition of a given species was
highly variable between individuals, it was stable
within individuals throughout infancy. Metabolic
composition and metabolic pathway abundance re-260 Cell Host & Microbe 17, 260–273, February 11, 2015 ª2015 Elsemained constant across time. A marked drop in
alpha-diversity was observed in T1D progressors in
the time window between seroconversion and T1D
diagnosis, accompanied by spikes in inflammation-
favoring organisms, gene functions, and serum and
stool metabolites. This work identifies trends in the
development of the human infant gut microbiome
along with specific alterations that precede T1D
onset and distinguish T1D progressors from non-
progressors.
INTRODUCTION
The initial colonization of the human gut microbiota begins in
utero (Aagaard et al., 2014) and is strongly influenced byvier Inc.
Figure 1. A Cohort to Assess the Dynamics
of the Developing Human Gut Microbiota in
Infancy
Individuals are represented in rows, and each
point is a stool sample. The size of the points
represents the number of serum autoantibodies
(0–5) that were positive at the time of the sample
collection. See also Figure S1.microbial exposures at birth (Dominguez-Bello et al., 2010). The
initial seeding and development of this community may have
long-term physiological consequences. Low-resolution longi-
tudinal studies in 14 infants (Palmer et al., 2007) and higher-
resolution studies in a single infant (Koenig et al., 2011) have
documented the gradual increase in phylogenetic diversity,
nonrandom community assembly, the effects of introducing
table foods, and the large taxonomic shifts that can occur during
infancy. High-resolution multi’omic studies that examine the
dynamics of infant gut microbiome development in a large, lon-
gitudinal cohort have been lacking, though one recent study has
shown that children with severe acute malnutrition exhibit
decreased ‘‘microbiota maturity’’ using such a cohort (Subrama-
nian et al., 2014). Events in early microbiome development may
have a role in promoting susceptibility to or protection from dis-
ease later in life; this has been demonstrated in mice (Cho et al.,
2012; Cox et al., 2014), and it may also be true for type 1 diabetes
(T1D) (Brown et al., 2011; Giongo et al., 2011; de Goffau et al.,
2013).
T1D is an autoimmune disorder that results from T cell-
mediated destruction of the insulin-producing b cells of the
pancreatic islets. Although approximately 70% of T1D cases
carry predisposing HLA risk alleles, only 3%–7% of children
with those alleles develop T1D (Achenbach et al., 2005), sug-
gesting a significant nongenetic component to the disease.
The incidence of T1D has been increasing rapidly over the past
few decades, particularly in the youngest age groups (0–4 years)
(Harjutsalo et al., 2008), suggesting a significant nongenetic
component to the disease. The incidence of T1D is particularly
high in Finland, where 1 in 120 children develop T1D before 15
years of age (Knip et al., 2005).
Although there have been limited human studies of the micro-
biome in T1D to date, the notion that T1D pathogenesis may be
influenced by microbial exposures has been well established in
murine models. The knockout of MyD88, an adaptor down-Cell Host & Microbe 17, 260–273,stream of multiple Toll-like receptors
involved in microbial sensing, in the
NOD mouse results in complete protec-
tion from diabetes (Wen et al., 2008).
Further, heterozygous MyD88KO/+ NOD
mice, which normally develop robust dis-
ease, are protected from diabetes when
exposed from birth to the gut microbiota
of a MyD88-KO NOD donor (Wen et al.,
2008). Therefore, disease progression in
the NOD mouse is driven in part by an
exaggerated innate immune response to
symbiotic microbiota, and altering the
composition of the microbiota can curtailthis response and prevent disease. Prospective studies are
required to assess whether the microbiota is similarly involved
in human T1D progression; however, such cohorts are exceed-
ingly difficult to build (Brown et al., 2011; Giongo et al., 2011).
Here, we assess the composition of the gut microbiota in a
densely sampled, prospective, longitudinal cohort of 33 HLA-
matched infants followed from birth until 3 years of age. We
use this unprecedented sample resolution to describe the dy-
namics and stability of the developing microbiome in the infant
gut of an at-risk T1D cohort. We show that although there are
significant shifts in taxonomic composition over time, the relative
abundance of metabolic pathways within individuals remains
remarkably constant throughout infancy. We identify a 25%
drop in alpha-diversity in children who progress to T1D com-
pared to controls, which occurs after seroconversion but before
disease diagnosis, and identify alterations to both the phyloge-
netic and metabolic pathway composition of the microbiome
during this time that is characteristic of a proinflammatory envi-
ronment. Our results demonstrate significant alterations to the
gut microbiome in T1D progressors prior to disease onset.
RESULTS
Extensive Characterization of the Infant Gut Microbiota
in a Longitudinal Cohort
To characterize the development of the infant gut microbiome
and the relationship between the gut microbiota and islet auto-
immunity and progression to T1D, we assembled a prospective,
longitudinal collection of stool samples from infants at risk for
disease (Figure 1). Infants from Finland and Estonia were re-
cruited at birth based on HLA risk genotyping (Table 1 and see
Table S1 available online). Parents collected their infants’ stool
at approximately monthly intervals. The cohort was comprised
of 33 infants, 11 of whom seroconverted to serum autoantibody
positivity (referred to hereafter as ‘‘seroconverters’’; defined asFebruary 11, 2015 ª2015 Elsevier Inc. 261
Table 1. Summary of Study Cohort
Subject ID
Country
of Origin T1D Status HLA Type Autoantibody Positive
Age at
Seroconversion
(Days)
Age at
T1D Diagnosis
(Days)
T026177 Estonia nonconverter DQB1*0302/*0501-DRB1*0401 N/A N/A N/A
T025411 Estonia nonconverter DQB1*0302/*0501-DRB1*0404 N/A N/A N/A
T014292 Estonia nonconverter DQA1*05/*03-DQB1*02/*0301 N/A N/A N/A
T012808 Estonia nonconverter DQA1*05/*0201-DQB1*02/*02 N/A N/A N/A
E029817 Finland nonconverter DQB1*0302/*04-DRB1*0404 N/A N/A N/A
E026325 Finland nonconverter DQB1*0302/*0501-DRB1*0404 N/A N/A N/A
E022852 Finland nonconverter DQB1*0302/*0501-DRB1*0404 N/A N/A N/A
E021406 Finland nonconverter DQB1*0302/*0302-DRB1*0401/*0401 N/A N/A N/A
E018268 Finland nonconverter DQB1*0302/*0604-DRB1*0404 N/A N/A N/A
E017833 Finland nonconverter DQA1*05-DQB1*02/*04 N/A N/A N/A
E017824 Finland nonconverter DQB1*0302/*0604-DRB1*0404 N/A N/A N/A
E016924 Finland nonconverter DQA1*05-DQB1*02/*04 N/A N/A N/A
E013487 Finland nonconverter DQA1*05/*03-DQB1*02/*0302-DRB1*0401 N/A N/A N/A
E011279 Finland nonconverter DQB1*0302/*04-DRB1*0404 N/A N/A N/A
E010590 Finland nonconverter DQB1*0302/*04-DRB1*0401 N/A N/A N/A
E006673 Finland nonconverter DQA1*05/*03-DQB1*02/*0302-DRB1*0401 N/A N/A N/A
E006646 Finland nonconverter DQB1*0302/*0501-DRB1*0401 N/A N/A N/A
E006547 Finland nonconverter DQB1*0302/*0501-DRB1*0404 N/A N/A N/A
E004016 Finland nonconverter DQB1*0302/*0502-DRB1*0404 N/A N/A N/A
E003872 Finland nonconverter DQB1*0302/*0501-DRB1*0404 N/A N/A N/A
E003061 Finland nonconverter DQB1*0302/*0502-DRB1*0405 N/A N/A N/A
E001463 Finland nonconverter DQB1*0302/*04-DRB1*0401 N/A N/A N/A
T013815 Estonia seroconverter DQA1*05/*0201-DQB1*02/*02 IAA, GADA 350.4 N/A
E026079 Finland seroconverter DQB1*0302/*04-DRB1*0401 IAA, GADA 580.35 N/A
E022137 Finland seroconverter DQB1*0302/*0501-DRB1*0401 IAA, GADA, IA-2A,
ZNT8A, ICA
562.1 N/A
E018113 Finland seroconverter DQB1*0302/*04-DRB1*0401 IAA, GADA, IA-2A,
ZNT8A, ICA
587.65 N/A
E017751 Finland seroconverter DQA1*05-DQB1*02/*0604 IAA, ICA 175.2 N/A
E010629 Finland seroconverter DQB1*0302/*0501-DRB1*0401 IAA, GADA, ZNT8A, ICA 945.35 N/A
E003989 Finland seroconverter DQB1*0302/*04-DRB1*0401 IAA, GADA, ZNT8A, ICA 346.75 N/A
T025418 Estonia T1D case DQA1*0201/*03-DQB1*02/*0302-
DRB1*0404
IAA, GADA, IA-2A, ICA 540.2 879.65
E010937 Finland T1D case DQA1*05/*03-DQB1*02/*0302-DRB1*0401 IAA, IA-2A, ZNT8A, ICA 905.2 959.95
E006574 Finland T1D case DQB1*0302/*0501-DRB1*0401 IAA, GADA, IA-2A,
ZNT8A, ICA
532.9 1,339.55
E003251 Finland T1D case DQB1*0302/*0501-DRB1*0401 IAA, GADA, IA-2A,
ZNT8A, ICA
357.7 1,168
See also Table S1 and Table S2.being positive for at least two of the five autoantibodies analyzed
in this study; see Experimental Procedures), and of those, four
developed T1D within the time frame of this study (referred to
as ‘‘T1D cases’’; see Table 1 and Figure 1). The 11 seroconvert-
ers were matched with the 22 controls for gender, HLA geno-
type, and country.
Sequencing of the V4 region of the 16S rDNA gene was carried
out on a total of 989 samples using paired-end, partially overlap-
ping reads on the Illumina MiSeq V2 platform as previously
described (Caporaso et al., 2012), yielding a very high depth of262 Cell Host & Microbe 17, 260–273, February 11, 2015 ª2015 Elsesequencing with amean of 65,076 reads per sample. Taxonomic
profiling was performed using QIIME (Caporaso et al., 2010), and
functional profiling of microbial pathways was inferred from 16S
sequences with PICRUSt (Langille et al., 2013). In total, there
were 777 unique samples sequenced by 16S, with a median of
23 unique samples per individual (minimum 8, maximum 34);
the full OTU table is available in Table S2. Shotgunmetagenomic
sequencing was performed on a subset of 124 samples from 19
individuals, including all 11 seroconverters, with a median of 6
samples per individual (minimum 3, maximum 11) (Figure S1).vier Inc.
The median depth of sequencing was 2.5 Gb per sample. Phylo-
genetic community profiling of metagenomic data was per-
formed using MetaPhlAn (Segata et al., 2012), and functional
profiling of microbial pathways was characterized with HUMAnN
(Abubucker et al., 2012).
In addition to 16S and metagenomic sequencing, serum and
stool metabolomics were performed on the cohort. For each of
the 33 participants, 7 serum samples taken throughout the
experimental time frame (Table S1) were subject to metabolo-
mics and lipidomics, and all samples that were used for shotgun
metagenomics were also analyzed by stool metabolomics and
lipidomics (see Experimental Procedures).
GutMicrobial Metabolites and Functional Pathways, but
Not Taxonomies, Are Stable throughout Infant
Development
Principal coordinates analysis of the Bray-Curtis dissimilarity
between all 777 16S-sequenced samples revealed that age is
the strongest driver of the composition of the infant gut micro-
biome (Figure 2A). Age accounted for 18% of the variation
between samples, and showed a nearly linear gradient diago-
nally along the first and second principal coordinates. Similarly,
the Chao1 alpha-diversity, a measure of the number of distinct
microbes in a community, exponentially increased in early
development until reaching a maximum at 3 years of age
(Figure 2B).
We hypothesized that with increasing taxonomic diversity in
the developing gut comes an equivalent change in the meta-
bolic composition of the gut community; however, this was
not the case. The stool metabolomics beta-diversity distances
between samples did not have as strong of an age trend as
did taxonomies (Figure 2C), and the alpha-diversity of stool me-
tabolites was nearly flat across time, with the exception of a few
outlier very-early-time point samples that had a much lower di-
versity (Figure 2D). More strikingly, the relative abundance of
metabolic modules in the microbiome remained approximately
constant throughout time and across individuals (Figure 2E
shows all samples sorted by age across all individuals). Essen-
tially all pathways are encoded by all individuals from the
earliest to the latest time points. The evenness is higher in the
first few months until it stabilizes (Figure 2F). This may be
because the composition of the microbiome requires time to
‘‘settle’’ into its most optimal abundance of functional path-
ways, which is less evenly distributed than in the earliest time
points.
These results demonstrate a remarkable stability in the meta-
bolic pathway coding potential—and the metabolic content—of
the microbiome despite dramatic shifts of taxonomic composi-
tion throughout human infancy.
A Model of the Dynamics of the Developing Gut
Microbiome
The strength of the age effect in taxonomies and its consistency
across individuals suggested that there may be closely shared
phylogenetic trajectories that define the development of the
gut microbiome, in agreement with previous cross-sectional
studies in older children (Yatsunenko et al., 2012). To investigate
the driving forces behind this effect, we performed pairwise cor-
relations of the trajectories of abundance between all cladesCell Host &across time on a per-individual basis, excluding T1D cases. Cor-
relations were determined using CCREPE (Faust et al., 2012), a
tool designed to find significant correlations in sparse, composi-
tional data such as 16S sequencing data, which are prone to
spurious correlations. The Z score for each clade-clade pair
was summed across all individuals (excluding T1D cases),
revealing a small set of pairs with very strong correlations that
were consistent across most subjects. This allowed us to pro-
duce a network of the dynamics of the developing gut micro-
biome (Figure 3). Plotting the corresponding clade abundances
over time demonstrates a strongly shared dynamic relationship
across time, and across nearly all individuals, for many specific
clades in this developmental process. The resulting network at
the family level is shown in Figure 3; see Figure S2 for other
phylogenetic levels.
The Infant Gut Microbiome Remains Stable at the
Strain Level
Having investigated the dynamics of the infant gut microbiome,
we examined its strain-level stability, i.e., the retention of mi-
crobial strains across time. Using the shotgun metagenomics
data available on 124 samples, we analyzed strain-level
markers on a per-species and per-individual basis using Meta-
PhlAn (Segata et al., 2012). Analysis was restricted to species
that have a mean of at least 13 coverage across all time
points per individual; 21 species and 12 individuals met this
requirement. Using an unweighted discordant marker distance
metric (see Supplemental Experimental Procedures), we found
that samples were more similar in the intraindividual versus
interindividual comparison (p < 1e-5; Figure 4A), suggesting
that the strain profile for a given species is more similar be-
tween samples in a single individual than between samples
in two people. Surprisingly, the strain profile remained essen-
tially constant over time for almost all species and in almost
all individuals (Figure 4B shows a representative example in
which the marker abundance is constant over time (individuals
#2 and #3). In a rare case we observed a shift in the strain
signature at a specific time point (individual #1). Table S3
shows marker abundances for all individuals with sufficient
marker coverage.
We investigated community stability by calculating the
Jaccard index, which is defined as the fraction of shared opera-
tional taxonomic units (OTUs), between all pairs of samples
within an individual in specified time windows (Figure 4C). For
instance, we calculated the fraction of shared OTUs within a
subject between two samples collected approximately 3 months
apart, and found that the Jaccard index is significantly higher
than for two samples from the same individual collected
6 months apart. As has been observed in an adult population
(Faith et al., 2013), we found that the Jaccard index followed a
power-law function (Figure 4C, line). The curve reached an
asymptote at a value of approximately 0.1, suggesting that
about 10% of bacterial strains (observed here at an OTU-level
resolution) were maintained in the infant gut from birth until 3
years of age (Figure 4C). This surprising result demonstrates
that although there is tremendous variability in the gut micro-
biome through infancy, the community at 3 years of age retained
a nonnegligible fraction of members that it acquired just after
birth.Microbe 17, 260–273, February 11, 2015 ª2015 Elsevier Inc. 263
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Figure 2. Gut Microbial Taxonomies Shift Dramatically, whereas Microbial Metabolites and Metabolic Pathways Remain Relatively Stable
throughout Infant Development
(A) Principal coordinates analysis on the unweighted UniFrac distances between samples based on 16S sequencing. Samples are colored by age at stool
collection.
(B) Alpha-diversity using the QIIME ‘‘observed species’’ metric on 16S sequencing.
(C) Principal coordinates analysis on stool metabolomics data.
(D) Shannon’s diversity measured on stool metabolomics data.
(E) Bars indicate relative abundances of KEGGmetabolic modules: A, aminoacyl tRNA; B, arginine and proline metabolism; C, aromatic amino acid metabolism;
D, branched-chain amino acid metabolism; E, carbon fixation; F, central carbohydrate metabolism; G, cofactor and vitamin biosynthesis; H, cysteine and
(legend continued on next page)
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Figure 3. Temporal Dynamics of Microbial Taxonomies in Infant Gut Development
Family-level network diagram of the correlation between clades in their trajectories across time, excluding individuals with T1D. Positive correlations are in blue,
negative correlations are in red, and the line thickness is proportional to the strength of the correlation (cumulative CCREPE Z statistic). The plots show the
abundance of the indicated family as a smoothing spline across all healthy individuals with a 95% confidence interval (shaded region). See also Figure S2.Correlations between the Gut Microbiome and Diet and
Environmental Factors
Extensive metadata relating to both clinical and nonclinical fac-
tors were collected for each participant in the study (Table S1),
allowing us to assess the association between the gut micro-
biome and environmental factors in our cohort. To avoid the po-
tential confounding effects of age, multiple sampling from the
same individual, and each of the other metadata, all analyses
were performed on a reduced set of samples in a limited time
frame, using age and other metadata as fixed effects and subject
identity as a random effect. This analysis was performed using
multivariate association with linear models (MaAsLin) (Morgan
et al., 2012), an additive general linear model with boosting
that can capture the effects of a parameter of interest while de-
confounding the effects of other metadata. This is particularlymethionine metabolism; I, fatty acid metabolism; J, glycosaminoglycan meta
metabolism; N, lysine metabolism; O, methane metabolism; P, nitrogen metabolis
metabolism; T, polyamine biosynthesis; U, purine metabolism; V, pyrimidine me
terpenoid backbone biosynthesis.
(F) A measure of evenness of KEGG metabolic modules.
Cell Host &important in the current study, as age, diet, and other factors
are expected to have strong influences on community composi-
tion (Table S1; see Experimental Procedures for the metadata
included in the MaAsLin analysis). With MaAsLin, we focused
our analysis on a single variable of interest, and systematically
‘‘subtracted out’’ the effect of each of the other potentially con-
founding metadata variables. A series of five samples from each
breastfed subject taken during and after cessation of breast-
feeding revealed an increase in Bifidobacterium and Lactoba-
cillus species during breastfeeding; however, we found that the
reduction in Lachnospiraceae was an even stronger effect (Fig-
ure S3A).We observed substantial differences between Estonian
and Finnish infants, including significantly higher levels of
Bacteroides and Streptococcus species, which contain a num-
ber of potential pathobionts, in the Estonians (Figure S3B).bolism; K, histidine metabolism; L, lipid metabolism; M, lipopolysaccharide
m; Q, nucleotide sugar; R, other amino acid metabolism; S, other carbohydrate
tabolism; W, serine and threonine metabolism; X, sulfur metabolism; and Y,
Microbe 17, 260–273, February 11, 2015 ª2015 Elsevier Inc. 265
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Figure 4. Bacterial Strains Are Stably Maintained in the Infant Gut throughout Development
(A) Distance between samples between subjects (interindividual) and within subjects (intraindividual) based on MetaPhlAn clade-specific strain marker
analysis.
(legend continued on next page)
266 Cell Host & Microbe 17, 260–273, February 11, 2015 ª2015 Elsevier Inc.
Additionally, we observed specific shifts in phylogenetic abun-
dance with several other dietary parameters: eggs, barley, soy,
and fish (nonsignificant) (Figure S3C). Notably, these shifts are
less significant than those associated with geography or breast-
feeding. Although we included antibiotic usage as a fixed effect
for all MaAsLin analyses in this study, we did not have sufficient
annotation on the timing of antibiotic usage to identify commu-
nity shifts associated with antibiotics. We did not find differences
in community composition between cesarean section versus
vaginally delivered infants, perhaps because our cohort included
only three cesarean-delivered subjects.
Gut Microbiota Composition Distinguishes T1D Status
We next examined whether there were features of the microbial
community that could distinguish T1D disease state. We
assessed Chao1 alpha-diversity across time in nonconverter
(not seroconverted), seroconverted (not diagnosed with T1D),
and T1D cases (seroconverted subjects also diagnosed with
T1D). We observed a pronounced flattening of the alpha-
diversity in T1D subjects at a time when the gut communities
of the nonconverter and seroconverted individuals continued
to rise in alpha-diversity (Figure 5A). This result was significant
by permutation test on subject labels (p < 0.025; Figure S3D).
Intriguingly, this divergence in alpha-diversity occurred after
the time period in which most subjects seroconverted, but
before the progressors presented with clinical disease.
To investigate the specific changes to the community that
accounted for the decreased alpha-diversity in T1D subjects,
we used MaAsLin analysis to focus on the time of the alpha-
diversity divergence, after 600 days of age, and observed a
number of significant alterations that distinguish T1D cases
from nonconverters and seroconverters (Figure 5B). After cor-
recting for potential confounding variables, we found that the
drop in alpha-diversity in T1D cases could be accounted for by
the relative overabundance of a few groups:Blautia, the Rikenel-
laceae, and the Ruminococcus and Streptococcus genera
(not statistically significant). These groups of bacteria contain
species that have been characterized as ‘‘pathobionts’’ (Chow
and Mazmanian, 2009), which are members of the commensal
microbiota that have the capacity to behave as pathogens. Our
shotgun metagenomic sequencing revealed that specific patho-
biont-like species within these groups, such as Ruminococcus
gnavus and Streptococcus infantarius, showed a spike in relative
abundance within the T1D cases at the time of alpha-diversity
divergence (Figure 5C). Conversely, we saw a relative under-
abundance of a few groups of bacteria that are commonly
depleted in the inflammatory state, namely the Lachnospiraceae
and Veillonellaceae (not statistically significant) (Figure 5B), and
metagenomic sequencing showed the complete absence of a
number of these species, such as Coprococcus eutactus and
Dialister invisus, in T1D cases (Figure 5C). Remarkably, sero-
converters had an intermediate abundance of all of these groups(B) Shown is the MetaPhlAn clade-specific strain marker profile for a single repre
represent the 37markers for this species, rows represent samples, and arrows ind
undergo a change in abundance in individual 1.
(C) The Jaccard index (fraction of shared OTUs) between pairs of samples fro
0–1.5 months, 6 indicates 4.5–6 months). The Jaccard index is shown for all pairs
the boxplots (line). The box represents the first and third quartiles, and error bar
Cell Host &of organisms between nonconverters and T1D cases (Figure 5B),
providing further evidence that this shift in microbiome composi-
tion is linked to the T1D disease state.
Gut Microbial Gene Content Is Altered Prior to Clinical
Onset of T1D
The NIH Human Microbiome Project has shown significant
stability in microbial metabolic pathways across individuals
despite high variability in taxonomic composition (HumanMicro-
biome Project Consortium, 2012). We investigated whether
changes in the abundance of specific metabolic pathways
correlatedwith T1D status. After correcting for the effects of con-
founding variables such as age and diet using MaAsLin, we
found significant shifts that occurred within T1D cases including
an increase in the multiple sugar transport system, which is
involved in the utilization of D-galactose, D-xylose, L-arabinose,
D-glucose, and D-mannose, and a decrease in the biosynthesis
of a number of amino acids (Figure 6A). A shift in functional
potential from the synthesis of nutrients to the passive transport-
ing-in of nutrients is characteristic of auxotrophic organisms.
Auxotrophs thrive in inflammatory environments where dead
tissue provides easy access tomany nutrients that are less avail-
able in the healthy gut (Morgan et al., 2012). As was found for
T1D-associated phylogenies, seroconverters had an intermedi-
ate level of abundance between nonconverters and T1D cases
in metabolic pathway carriage (Figure 6A), and weremore similar
to nonconverters than T1D cases.
Serum and Gut Lipids and Metabolites Relevant to
Disease Are Correlated with T1D-Associated Microbial
Taxa
The physiological effects of the gut microbiota extend beyond
the gut; there is an interplay between both host and microbial
enzymes and their metabolites which impacts host metabolism
(Velagapudi et al., 2010) and mucosal immunity (Smith et al.,
2013), as well as diseases including cardiovascular disease
(Koeth et al., 2013; Wang et al., 2011). We assessed the correla-
tion between serum polar metabolites and lipids with the gut
microbiota. A Spearman correlation between absolute abun-
dances of metabolites and microbial relative abundances
yielded several metabolite-microbe clusters (Figure S4). Most
significantly, we observed a clustering of triglycerides with a
number of microbes, including a positive correlation between
Blautia and long-chain triglycerides and Ruminococcus with
short-chain triglycerides, and a negative correlation between
Veillonella and short-chain triglycerides (Figure 6B). At the OTU
level, we also observed correlations between members of these
genera with branched-chain amino acids, specifically a positive
correlation with Blautia and Ruminococcus members and a
negative correlation with a Veillonella member (Figure 6C).
Altered levels of serum triglycerides are a common feature of
obesity and type 2 diabetes, and hypertriglyceridemia issentative species (Bacteroides ovatus) for three separate individuals. Columns
icate discordant markers between individuals 2 and 3 and indicate markers that
m the same individual within the indicated time window (i.e., 1.5 indicates
of samples across all subjects. A power-law curve was fitted to the medians of
s indicate 95% confidence of median. See also Table S3.
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Figure 5. The gut Microbiota Distinguishes Disease Status in T1D prior to Diagnosis
(A) Plot of Chao1 alpha-diversity across time, represented as a smoothing spline with a 95% confidence interval (shaded region). The seroconversion window
indicates the first and third quartiles for age at seroconversion for all seroconverted and T1D-diagnosed individuals, and the diagnosis window indicates the first
quartile of time at T1D diagnosis (third quartile is 1,211 days).
(B) Abundances of the significantly differentially abundant taxa between T1D versus nonconverter and seroconverted individuals, including only samples
between the seroconversion and diagnosis windows. FDR-corrected p values (Q values) were calculated using MaAsLin. The box represents the first and third
quartiles; error bars indicate 95% confidence of median.
(C) Plots of the relative abundance of representative species from shotgunmetagenomics data, represented as a smoothing spline with a 95%confidence interval
(shaded region). See also Figures S3 and S5.associated with poor glycemic control and nephropathy in T1D
(Alcantara et al., 2011; Verge`s, 2009). Additionally, elevated
branched-chain amino acids have been shown in both patients
(Vannini et al., 1982) and in mouse models (Mochida et al.,
2011; Sailer et al., 2013) of diabetes, as well as preceding islet
autoimmunity in children who later progress to T1D (Oresic
et al., 2008). We found a positive correlation between Blautia
and Ruminococcus, both of which have increased abundance
in T1D cases, with triglycerides and branched-chain amino
acids, possibly indicating that these microbe-metabolite rela-
tionships cooperatively impact T1D progression.
To conduct an integrative analysis of the correlations that
exist between the gut microbiome and the gut (stool) metabo-
lome, we performed penalized canonical correlation analysis268 Cell Host & Microbe 17, 260–273, February 11, 2015 ª2015 Else(Figures 6D; see Experimental Procedures). This analysis identi-
fied a canonical variate that associates increased Ruminococ-
cus and decreased Veillonella abundance with increased sphin-
gomyelin and decreased lithocholic acid levels (Pearson R =
0.61; Q = 0.03). Sphingomyelin is a member of the sphingoli-
pids, which inhibit intestinal natural killer T cell function and pro-
tect against oxazolone-induced colitis (An et al., 2014). Litho-
cholic acid, similar to deoxycholic acid, is a secondary bile
acid that promotes intestinal inflammation by eliciting reactive
oxygen and nitrogen species and activating NF-kB activity in in-
testinal epithelial cells (Lee et al., 2004; Mu¨hlbauer et al., 2004;
Payne et al., 2007; Sears and Garrett, 2014; Da Silva et al.,
2012). Although the alterations to the microbiota that we
observed may be related to impaired glucose metabolism invier Inc.
the prediabetic stage, these results suggest that the T1D-asso-
ciated microbiota that becomes established prior to disease
onset may actively promote a metabolic environment in the
gut that is permissive to inflammation and promotes
pathogenesis.
DISCUSSION
To identify and understand alterations to the gut microbial com-
munity composition that may contribute to childhood disease,
we must first investigate the normal dynamics of the community
in the developing infant. Here, we identify a set of principles that
describemicrobiome development in the infant gut.We note as a
caveat that all children in this cohort carry T1D-predisposing
HLA alleles and are restricted to the countries of Finland and
Estonia, and are therefore not necessarily representative of
genetically ‘‘normal’’ infants in other regions of the world. First,
although there is great variation in overall taxonomic com-
position between and within individuals over time, there is sig-
nificantly less variation in the metabolic composition of the
microbiome, and almost no variation in its metabolic pathway
coding potential. This result provides a variation on the finding
made in the NIHHumanMicrobiome Project regarding the stabil-
ity of metabolic pathways in the microbiome between healthy
adults (Human Microbiome Project Consortium, 2012) and sug-
gests that the relative proportions of bacterial functional path-
ways remains the same from soon after birth until 3 years of
age. We speculate that because the taxonomic composition of
the microbiome stabilizes at approximately 3 years, functional
pathways likely remain stable for long after this age as well.
Second, we identified shared taxonomic trajectories, remark-
ably consistent across individuals, that indicate general changes
in abundance, the timing of these shifts, and the relationships
between community members. For example, we saw a strong
positive correlation between the Lachnospiraceae and Rumino-
coccaceae, both Gram-positive anaerobes that are inversely
correlated with the Enterobacteriaceae, Gram-negative aer-
obes. In turn, the Enterobacteriaceae are positively correlated
with the Bifidobacteriaceae, which decrease in abundances
after cessation of breastfeeding. Although there are many ex-
ceptions to general trends, we observed a decrease in Gram-
negative bacteria over time, and found that early colonizers are
aerobic, whereas later colonizers tend to be anaerobic. Similar
trends have been observed previously (Dominguez-Bello et al.,
2010; Koenig et al., 2011; Palmer et al., 2007); however, the
significantly higher density of sampling, size, and longitudinal
nature of our cohort provide a high-resolution map of these
dynamics and demonstrate how universal they are across
infants.
Third, we demonstrated a surprising stability in the mainte-
nance of specific strains through time. Although the strain
composition is quite distinct between individuals, as expected,
the strain composition within an individual remains essentially
constant throughout infancy for almost all individuals and almost
all species that have sufficiently high abundance for stability
analysis.
In addition to shared trends, we identified aspects of infant gut
microbiome development that are unique to the T1D state. We
observed a significant alteration in the structure of theCell Host &T1D-associated gut microbiome: a relative 25% reduction in
alpha-diversity compared to nonconverters and seroconverters,
associated with shifts in both microbial phylogenetic and meta-
bolic pathways. Importantly, this shift is seen in children who are
diagnosed with T1D within the study time frame, but not in sero-
converters without disease. Although the probability of progres-
sion to T1D after positivity for two islet autoantibodies is greater
than 80% after follow-up for 15 years (Ziegler et al., 2013), there
is significant variability in when progression occurs, ranging from
weeks to more than two decades (Knip et al., 2010), and the fac-
tors contributing to this variability are not well understood. The
logistics of densely sampling a large cohort of individuals
through T1D diagnosis limits the time frame of such a study,
and we therefore are reporting on a special subset of T1D cases
with early onset diabetes (EOD) (Harjutsalo et al., 2013). We pro-
vide evidence that pronounced alterations occur in the gut mi-
crobiome that precede overt disease.
Although previous studies of human cohorts have been con-
strained by the availability of sufficient longitudinal samples
and subject groupings that distinguished seroconverting
non-progressors from T1D progressors, they have shown a
decreased microbial diversity in children with long-lasting b
cell autoimmunity and in progressors to clinical T1D compared
to nonseroconverted controls (Brown et al., 2011; Giongo
et al., 2011; de Goffau et al., 2013). Here, we demonstrated
that this shift occurs prior to onset of disease but after serocon-
version, and identified that it is specific to T1D progressors and
not seen in seroconverterswithout disease. Decreasedmicrobial
diversity is a hallmark of dysbiosis and has been observed in
obesity (Turnbaugh et al., 2009), inflammatory bowel disease
(Manichanh et al., 2012), and Clostridium difficile-associated
diarrhea (Chang et al., 2008). A recent study showed that a failure
to establish a critical level of diversity in the gut microbiota of
developing mice resulted in long-term increases in IgE levels,
thus predisposing mice to immune-mediated disorders (Cahen-
zli et al., 2013). Decreased diversity results from the blooming of
a small subset of the community that crowds out other commu-
nity members.
Additionally, we find higher levels of human b-defensin 2
(hBD2) in early samples of children who develop T1D (Fig-
ure S5). hBD2 is an antimicrobial product induced by colonic
epithelial cells during inflammation (O’Neil et al., 1999; Weh-
kamp et al., 2005); therefore, this result is supportive of
increased intestinal inflammation in the cohort of children who
go on to develop T1D. It has been proposed that an aberrant
gut microbiota, a permeable intestinal mucosal barrier, and an
altered mucosal immune response collectively contribute to
the development of T1D (Vaarala et al., 2008). Our results
prompt further functional studies to determine whether the
proinflammatory microbiome we observe to bloom prior to clin-
ical disease onset may take advantage of or drive increased in-
testinal permeability and intestinal inflammation to contribute to
T1D pathogenesis.EXPERIMENTAL PROCEDURES
Study Cohort
Please see Supplemental Experimental Procedures for cohort recruitment and
sample and information collection details.Microbe 17, 260–273, February 11, 2015 ª2015 Elsevier Inc. 269
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Stool Sample Collection and DNA Extraction
Stool samples were collected by participants’ parents and stored in the house-
hold freezer (20C) until the next visit to the local study center; samples were
then shipped on dry ice to the DIABIMMUNE Core Laboratory. The samples
were then stored at80C until shipping to the Broad Institute for DNA extrac-
tion. DNA extractions from stool were carried out using the QIAamp DNA Stool
Mini Kit (QIAGEN, Inc., Valencia, CA, USA).
Sequencing and Analysis of the 16S Gene and Shotgun
Metagenomics
16S sequencing and metagenomics was performed essentially as previously
described (Gevers et al., 2014). Additional details are available in the Supple-
mental Experimental Procedures.
Phylogenetic Abundance Trajectory Network Analysis
Analysis was limited to the 29 individuals without T1D. Samples from the 16S
OTU abundance table were binned into 20 time windows from 50 to
1,100 days, selecting the nearest sample in time for each bin. Read counts
from the 16SOTU abundance table were collapsed at each phylogenetic level,
from phylum to genus, and compositionally normalized such that the
abundance in each sample sums to one. At each phylogenetic level, on a
per-individual basis, the correlation between every clade-clade pair was per-
formed in CCREPE (http://huttenhower.sph.harvard.edu/ccrepe; previously
known as ‘‘ReBoot’’; Faust et al., 2012). The default similarity metric,
Spearman, was used. Only correlations with a Q value < 0.1 were included
in analysis. For each filtered clade-clade pair, the Z statistic was summed
across all 29 individuals, and only pairs with a cumulative absolute Z statistic
value of >20 were carried forward, as this was a conservative cutoff for consis-
tent correlations across many subjects. The cumulative Z statistic was scaled
without centering using the R ‘‘scale’’ function and then visualized as a network
diagram on Cytoscape.
Human b-Defensin 2 Measurement from Stool Samples
Frozen stool samples were thawed at room temperature immediately prior to
analysis. Fecal human b-defensin 2 (hBD2) levels were determined by enzyme
linked immunoabsorbent assay (ELISA) using the b-defensin 2 ELISA Kit (Im-
mundiagnostik, Bensheim, Germany) adapted for fecal samples as described
previously (Kapel et al., 1999).
Metabolomics and Lipidomics Profiling from Serum and Stool
Please see Supplemental Experimental Procedures for detailedmetabolomics
and lipidomics protocols and sample handling information.
Community Stability Analysis
The Jaccard index for a given sample pair is defined as (sample AX sample B)/
(sample A W sample B) and calculated using the compositionally normalized
16S OTU table. On a per-individual basis, the Jaccard index was calculated
for all samples that fell into time windows of 1.5 months in length, beginning
at 0–1.5 months up to 31.5–33 months.
MaAsLin Analysis
MaAsLin analysis was performed using default parameters (http://
huttenhower.sph.harvard.edu/maaslin). Subject ID was used as a random
effect. The following variables were used as fixed effects for every analysis,
in addition to the variable of interest: T1D status, age, gender, country, delivery
mode, time and name of antibiotic exposure, total reads per sample,
sequencing batch ID, breastfeeding (on/off), solid food (on/off), eggs (on/off),Figure 6. Gut Microbial Gene Content and Serum and Gut Metabolites
(A) Abundances of the significantly differentially abundant KEGG modules betwe
seroconversion and diagnosis windows. FDR-corrected p values (Q values) were
bars indicate 95% confidence of median.
(B and C) (B) Spearman correlations between serum triglycerides and the five m
OTUs using a cutoff of p < 0.001. +, correlations with p < 0.05; *, correlations wi
(D) Spearman correlations between stool metabolites and lipids and the most-cor
Veillonella, and correlated metabolites obtained using penalized canonical corre
Cell Host &fish (on/off), soy products (on/off), rye (on/off), barley (on/off), and buckwheat
and millet (on/off).
Alpha-Diversity
Alpha-diversity analysis of the 16S OTU table was performed in QIIME 1.5.0
(Caporaso et al., 2010) with the alpha_diversity.py script using the ‘‘chao1’’
metric and default parameters. Permutation-based analysis of significance
was performed on a per-subject basis by shuffling the T1D subject label
through all individuals and recalculating the difference in Chao1mean between
T1D subjects versus control and seroconverted subjects. Ten thousand
permutations were performed.SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
five figures, and three tables and can be found with this article at http://dx.
doi.org/10.1016/j.chom.2015.01.001.
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